Peptonic Medical AB (publ) org nr 556776-3064
(www.spotlightstockmarket.com, ticker: PMED)
2022 second quarter (Apr-Jun)
- Net sales of products KSEK 12 354 (7 356)
- Gross profit KSEK 6 269 (4 863), Gross margin 51% (66%)
- Operating loss KSEK -8 146 (-12 271)
- Loss per share SEK -0.04 (-0.06)
2022 first half year (Jan-Jun)
- Net sales of products KSEK 21 262 (18 747)
- Gross profit KSEK 11 865 (11 439), Gross margin 56% (61%)
- Operating loss KSEK -19 021 (-18 851)
- Loss per share SEK -0.08 (-0.10)
From the CEO
Improved sales and improved results
It is satisfying that we in this quarter are improving both sales and earnings significantly. The improvements regard in comparison to the previous quarter and the corresponding period last year.
The sales development is explained by the positive development of sales of vaginal self-tests to international license partners in the US and the EU. We have also continued positive development of our own brand VagiVital in the home market Sweden. During the quarter, the new VagiVital VS, self-test to identify vaginal infections, was launched in Sweden.
Change in gross margin 51% (66%) in comparison with the corresponding quarter of the previous year is explained by an increasing share of sales to international partners with higher volume but lower margin. With the acquisition of CommonSense Israel, partner contracts with set prices were inherited. Prices are under renegotiation and will increase over time. In combination with increased efficiency in production, this will have a positive effect on the gross margin.
Well positioned to meet current social trends
Looking forward, we see continued positive development. The company’s new strategy and core business with clinically proven intimate self-care based on the diagnose/treat/prevent principle meets a strong social trend, which is reflected in growing sales and a strong order backlog. We continue with great focus on our work to create a unique and market-leading portfolio at the same time we build sales and improve results. According to the previous communicated information in the quarter one report, additional external capital will be needed.
August 18th, 2022
Erik Sundquist, VD
Revenue – Sales of goods during the second quarter amounted to SEK 12 354 (7 356) thousand. Other operating income for the quarter was SEK 329 (14) thousand. During the first half of the year, sales of goods amounted to SEK 21 262 (18 747) thousand. Other operating income for the half year was SEK 850 (4) thousand.
Costs – Costs for the second quarter amounted to SEK -20 829 (-19 641) thousand. Costs of goods for the second quarter amounted to SEK -6 085 (-2 493) thousand. Costs of goods for the first half year amounted to SEK -9397 (-7 308) thousand.
Profit – The company’s profit after net financial items for the second quarter amounted to SEK -9 043 (-12 280) thousand. For the first half year the corresponding amount is SEK -20 301 (-18 918) thousand.
Financial position and liquidity – Cash and bank amounted to SEK 9 836 (21 140) thousand as of June 30th, 2022.
Shareholders ’equity – The group’s shareholders’ equity as of June 30, 2022, amounted to SEK 62,416 (106,526) thousand, which gives an equity / assets ratio of 67 (89) percent.
Liabilities – The group’s liabilities, as of June 30, 2022, amounted to SEK 30,471 (13,087) thousand.
Organization – During the period, the average number of employees was 31 (18). At the end of the period, the number of employees was 31 (16).
Share – The total number of shares as of June 30, 2022 was 242,743,544 (191,639,642).
For key figures, income statement, balance sheet, statement of cash flow and changes in equity, download complete year end report as PDF:
Review and certification
This interim report has not been reviewed by the Company’s auditors.
The Board of Directors and the CEO certifies that the interim report gives a fair overview of the business, position and profit or loss of the Company.
- Quarterly report, 3: 2022-11-10
- Year-end report, 2022: 2023-02-24
Stockholm den 18 August 2022
Jan Bardell, Chairmen of the Board
Susanne Axelsson, Board member
Lena Munkhammar, Board membe
Anders Norling, Board member
Erik Sundquist, CEO
For more information please contact:
Erik Sundquist, CEO PEPTONIC medical AB.
Phone: +46 722 499 043